Alluvi, formerly BI 4744, offers a notable advance in obesity care. This dual agonist targeting both GLP-1 and GIP targets demonstrates impressive results in patient trials, possibly surpassing current GLP-1 target https://alluvi-healthcare174045.gynoblog.com/profile